Description

A synthetic lipidated triple agonist at the GLP-1, GIP, and glucagon receptors, enabling once-weekly dosing. Adding glucagon-receptor agonism is studied for increased energy expenditure and hepatic fat mobilization alongside incretin effects.

Key research notes:

• Body-weight reduction in Phase 2 obesity trials (NEJM 2023)
• Glycemic control in type-2 diabetes
• Effects on hepatic fat / energy expenditure

Specifications: CAS: 2381089-83-2 · Formula: C₂₂₁H₃₄₂N₄₆O₆₈ · Molar mass: 4731.33 g/mol · Form: Lyophilized powder · Storage: −20 °C (2–8 °C reconstituted)

Reconstitution: Add 2 mL BAC water → 5 mg/mL (1 mg = 20 units). Or 1 mL → 10 mg/mL (1 mg = 10 units).

Research dosing reference (reported in research, not usage instructions): Reported in trials: subcutaneous once-weekly with gradual escalation (studied ~1–12 mg weekly) under medical supervision. As with all GLP-1-class agonists, unsupervised use is hazardous.

Research use only. Not for human consumption.